A concern regarding the upcoming androgen degrader drug GT20029
    Chat 1/25/2025

    At a glance
    In this general discussion post, the primary subjects mentioned are
    πŸ’§ GT20029 (topical)
    β€’ Finasteride (systemic)
    β€’ Dutasteride (systemic)
    β€’ RU58841
    the tone is 😐 neutral.

    Other terms

    GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
    View this post in the Community β†’

    Similar Community Posts Join

    5 / 251 results

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

      in Research/Science  126 upvotes 1 year ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 11 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community It’s over. NOTHING has worked.

      in Chat  95 upvotes 2 years ago
      A user who has been trying various treatments for hair loss for four years, with no success. Suggestions include use of minoxidil, finasteride, RU58841, microneedling, supplements and multivitamins, lifestyle changes, scalp biopsy, and SMP.

      community Pyrilutamide Phase 3 on its way

      in Treatment  128 upvotes 3 years ago
      Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

    Related Research

    6 / 6 results